Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy - Wikidata - wikimedia - TriplyDB

Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy

Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy

http://www.wikidata.org/entity/Q34556927

about

Exploiting tumor epigenetics to improve oncolytic virotherapy Oncolytic viruses as therapeutic cancer vaccines Thunder and lightning: immunotherapy and oncolytic viruses collide Pancreatic cancer from bench to bedside: molecular pathways and treatment options Viro-immune therapy: A new strategy for treatment of pancreatic cancer Promising oncolytic agents for metastatic breast cancer treatment Oncolytic viruses as anticancer vaccines Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity Handling of the cotton rat in studies for the pre-clinical evaluation of oncolytic viruses.Genome-wide lentiviral shRNA screen identifies serine/arginine-rich splicing factor 2 as a determinant of oncolytic virus activity in breast cancer cells.Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo.Designing Herpes Viruses as Oncolytics.Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity.Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.Modulation of chemokines in the tumor microenvironment enhances oncolytic virotherapy for colorectal cancer A polysaccharide isolated from Agaricus blazei Murill (ABP-AW1) as a potential Th1 immunity-stimulating adjuvant.Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments.Oncolytic vaccines.Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized cotton rat model of breast adenocarcinoma.Oncolytic Immunotherapy for Treatment of Cancer.Immune System, Friend or Foe of Oncolytic Virotherapy?Oncolytic viruses: adenoviruses.Newcastle disease virus mediates pancreatic tumor rejection via NK cell activation and prevents cancer relapse by prompting adaptive immunity.Reovirus FAST Protein Enhances Vesicular Stomatitis Virus Oncolytic Virotherapy in Primary and Metastatic Tumor Models.Vaccine adjuvant ginsenoside Rg1 enhances immune responses against hepatitis B surface antigen in mice.Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer.Carnitine transport and fatty acid oxidation.Tumor vascularization is critical for oncolytic vaccinia virus treatment of peritoneal carcinomatosis.Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.Oncolytic Virotherapy and the Tumor Microenvironment.Oncolytic influenza virus infection restores immunocompetence of lung tumor-associated alveolar macrophages.

P2860

Q21131237-F3E85264-44B7-4FCB-B7A9-ADC44FE5490E Q21245758-18D32EF5-035A-4ACF-8878-ED3C0E7F53FC Q24597894-CB270829-54A3-457D-B63D-8441B6D02D8C Q26747524-65ED2615-AD30-4FB2-854C-A47DB0FBAFBE Q26774641-0632F2FB-86A8-4C46-B08D-5A32AD99588B Q26830620-0E4B6C47-920E-4D1B-AA4B-F4B3E07BCB82 Q27025600-F61C41D8-5A45-458D-BBEF-ABCFA9CC1B13 Q30300159-C5851CA6-AE78-4710-90B2-88867D9CDE7C Q33679505-ED10EB21-A069-40EC-B43C-873643CAC5BA Q33743847-94AC187B-7807-4DCC-95EB-E2E1FAA76B61 Q35161325-9625042F-08C0-4E44-828F-417849CAFB7E Q35740932-ECE053C8-46CE-478D-BE38-6703944F0B26 Q35750051-20C42C2C-05AC-4DD3-8FB3-878C823BE48E Q36142487-7D4656DD-3F29-415D-AF9A-5B9E0A7BD0E6 Q36220618-8DB53F9E-8A1C-4D2A-BD29-CE5EB449577D Q36664245-F64A31BB-EB0A-4323-8A93-6649D3A6EBE9 Q36700481-B0907EF5-003E-4F73-BA43-8E16736240E3 Q37225501-D5F1DABA-7CC4-4B3B-B809-EF00063DAD82 Q37229386-CD9DE92D-D2AF-4BB0-86F2-948F91D68B46 Q37417271-03BE085F-D13F-4DA2-876F-B1F1D3E1201A Q37707676-75536A64-5A6D-4CCB-9E78-EBFC3CDA6EA7 Q38025696-EA32574F-B457-4DCF-A6FE-D95244E8F26F Q38119845-570BCE1C-63A7-4DFF-B390-245A40A8BF71 Q38152474-3576B2A2-D7D9-4D2A-AA23-4F7F34EE6603 Q38194135-195EAA54-8B29-4D9E-9827-71CBFBE522AD Q38223419-28063FF0-B064-4837-BCA7-96C9DF0DA841 Q38648891-A0D9DD4A-25FB-4004-B1D0-CA821D6A49C2 Q38845195-9AE359B2-807D-4CC9-8544-CC1C3CC957EA Q38848223-862A1509-26B2-4F6F-BE91-76779D287EFB Q39355854-32381841-BE80-4EB9-8CD6-8E942388BAAE Q39432063-3450C714-CAA3-494B-9DE0-6F760D59635B Q40063602-14C861D0-6058-48A8-BBAF-96A8DD3F68BC Q40064004-8BCEDE25-35D8-481A-94FC-6E2D52159103 Q40791130-A44A58A5-E240-4B72-91F6-F45F8CE76EA8 Q40907752-080059F1-4813-4CAB-8128-EBF728C861BD Q41633875-A0D8F219-B85F-4E27-8F41-04BFE97C0167 Q42280873-F02E256E-1E2C-4069-880A-5CBA3A2E1CCF Q47365404-92B25616-30A7-42ED-8962-E53AF86471F4 Q47560690-507B1EB9-9CD9-479B-8865-CCCC59E0C5BD Q53688637-289BD5AF-FB6B-4AB1-8F63-98EFDA9AF02F

P2860

Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapy

http://www.wikidata.org/entity/Q34556927

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy

@ast

Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy

@en

Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy

@nl

type

label

Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy

@ast

Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy

@en

Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy

@nl

prefLabel

Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy

@ast

Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy

@en

Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy

@nl

P1433

Q34556927-7FD03759-4F7C-4191-9653-5ED1DC74F5AE

P1476

Q34556927-BD45D788-9390-4706-9944-878260A3A692

P2093

Q34556927-077B0CB6-C883-417E-8499-888EB89403B7

Q34556927-7571158A-E96F-4DF5-AA29-E30681D9C47D

Q34556927-7E1D16EF-D502-4CC3-83DF-FCB61DB51FA9

Q34556927-BDFA8A16-2978-48F7-8A83-ABDEEB4AACC7

Q34556927-EA84ABFE-7291-47D8-A744-C92FFD28DED1

P2860

Q34556927-02F7AC55-F0BB-4051-B5C2-D418F31C51CC

Q34556927-033364B0-5489-4C06-B30E-CD6DAC02E918

Q34556927-049EA201-85A0-4086-9C84-9830FBD52D19

Q34556927-063CD0CC-46B5-4CC3-B610-99C0708E9CC5

Q34556927-0B524D61-FC17-414A-8297-4C37D21AF786

Q34556927-1DF2972E-453E-4CE6-B66F-6A7062382FC1

Q34556927-21A85940-16D4-4E0D-809D-909A6E69ADF9

Q34556927-256F8519-0167-4AA3-841A-198E7D787984

Q34556927-31265750-0061-47E2-A5C3-A5145CFB7669

Q34556927-356A3AD0-5F3B-4BAA-8F11-C8778123EF90

P304

Q34556927-94150774-C9A5-4C22-BE74-8BF2877A2C76

P31

Q34556927-245869F0-2432-4D48-BE7A-DE2998DDE491

P356

Q34556927-CFF74733-55FE-4C8C-8233-512084DD13FC

P433

Q34556927-9903B1EF-4097-48C2-AB3E-2E44CFF55523

P478

Q34556927-3547DE39-FDB9-4FCA-B34E-0796013AC3F7

P50

Q34556927-F13C5549-1727-490C-96FC-2914B47A7F9C

P577

Q34556927-C1B17091-E4C1-4910-94B3-CB4B0977E707

P5875

Q34556927-C168F829-5B57-4EF6-BB25-E7CFF93A0E5A

P698

Q34556927-D7B56816-E67F-432D-8CCF-7D457D8E5E27

P921

Q34556927-DC267450-89ED-49B4-8DC3-9F22B5141C2F

P932

Q34556927-C1C8B46B-22E6-4ACC-B2EE-D3D6A489C849

P356

P1433

Molecular Therapy

P1476

Adaptive antiviral immunity is ...... ccess of oncolytic virotherapy

@en

P2093

Brian D Lichty

http://www.w3.org/2001/XMLSchema#string

Jeanette E Boudreau

http://www.w3.org/2001/XMLSchema#string

Kyle Stephenson

http://www.w3.org/2001/XMLSchema#string

Paul T Sobol

http://www.w3.org/2001/XMLSchema#string

Yonghong Wan

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunotherapy: moving beyond current vaccines

Recombinant Newcastle disease virus as a vaccine vector for cancer therapy

How cells respond to interferons

Calreticulin exposure dictates the immunogenicity of cancer cell death

Transforming growth factor-beta regulation of immune responses

IRF family of transcription factors as regulators of host defense

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.

Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease

Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.

A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer.

P304

335-344

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2010.264

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Karen L Mossman

P577

2010-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49647027

http://www.w3.org/2001/XMLSchema#string

P698

21119618

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

3034857

http://www.w3.org/2001/XMLSchema#string